Matthew Scholz is the CEO of Immusoft, a (currently) Seattle based biotech startup that is commercializing technology to program the human immune system.
If Seattle is to occupy a future place of dominance in the biotech world, it must foster more of an “incubator” culture. There is a “valley of death” between the well-funded... Read more »